Mersana Teams With Teva To Develop Polymer Conjugate Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Linking fumagillin analogue with polymer should prevent CNS toxicities seen with previous fumagillin candidates.
You may also be interested in...
Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization
Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
Mersana Therapeutics Inc.
By linking drugs to a proprietary nanometer-scale polymer, Mersana Therapeutics can favorably affect properties of chemotherapeutic agents such as solubility, half-life, and accumulation in tumor tissue, thereby widening their therapeutic window.